This week AJMC is covering session highlights from the PBMI Annual Drug Benefit conference.
Medication Optimization in a New Healthcare Era
In medication use and improving patient outcomes, Susan Cooper, MPH, RPh, senior director, pharmacy services, HealthPartners, says her organization envisions prescription drug optimization going beyond addressing adherence. It seeks to improve the patient experience. Dr Cooper suggests that efficient optimization can underline the triple aim (quality, experience, and affordability) through successful integration approaches, including those that use technology.
Addressing underuse, overuse, and misuse of medications is important because nearly half of the current population do not currently adhere properly to medication. The reasons behind nonadherence vary—Dr Cooper says that it is easy to find thousands of studies that address the reasons, but “The bottom line is that there is no silver bullet or no 1 reason why people aren’t taking their medications.” Read more here.
A Comprehensive Medication Therapy Management (MTM) Program
James Gartner of CareSource and Patty Kumbera of OutcomesMTM shared the first-year results of a cooperative comprehensive medication therapy management (MTM) program that they implemented for nearly 1 million Ohio Medicaid members. As one of the country’s biggest Medicaid managed healthcare plans, CareSource provides consistency across MTM programs, including networking requirements, covered services policies and procedures, quality assurance, and documentation standards and reporting. OutcomesMTM leverages local relationships with pharmacists, patients, and prescribers while using innovative technology. Read more here.
Healthcare Industry Transformation to Meet Employer Demand for Managing Specialty Pharmacy Costs
According to Howard K. Crowley, head of pharmacy strategic initiatives, Aetna Pharmacy Management, a Towers Watson/ National Business Group on Health survey found that 29% of employers rank the rising costs of specialty drugs as a top challenge to keeping health benefit coverage affordable.
He says that while most prescriptions will be written for generic prescription drugs, most of the costs will be for specialty medication. In 2013 drug spending totaled $35 billion, but by 2021 is could be as high as $160 billion. He added that 77% of drug spend is associated with 6 therapeutic categories and 40% of drugs filed for FDA approval are specialty. Of course, specialty pharmacy costs are only part of the problem. Other challenges include the 90,000 projected shortfall of physicians by 2020, and the 46,000 projected shortfall of specialists by 2020. Read more here.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Read More
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Read More